Long-term Outcome of TNF Alpha Therapy in IBD
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 538
- 试验地点
- 1
- 主要终点
- Length of first TNF Alpha Therapy in IBD patients
研究概览
简要总结
The aim of this retrospective study is to assess the outcome of patients with inflammatory bowel disease (IBD) under TNF-alpha antibody therapy over a period of 20 years
详细描述
Long-term results published so far show that over the years a large part of patients have to stop TNF Alpha antibody therapy in IBD. Reasons are mostly loss of effectiveness or intolerance or side effects. Reasons for the termination are usually poorly characterized with regard to the exact reason and time. As a consequence, the aim of this retrospective study is to assess the outcome of patients with inflammatory bowel disease under TNF-alpha antibody therapy over a period of 20 years
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with a confirmed IBD diagnosis
- •TNF Alpha antibody therapy in the last 20 years at our outpatient clinic
排除标准
- •Not Meeting the inclusion criteria
- •Lack of clinical data, no follow up available
结局指标
主要结局
Length of first TNF Alpha Therapy in IBD patients
时间窗: 20 years
The main endpoint of this retrospective Analysis is the length of Treatment with the first TNF Alpha therapy in IBD
次要结局
- Number of side effects(20 years)
- Rate of further biologicals after first TNF Alpha therapy(20 years)
- Predictive factors(20 years)
- Rate of surgical interventions after first TNF Alpha(20 years)
- Reasons for discontinuing therapy(20 years)